Pre-transplant prognostic factors for patients with high-risk leukemia undergoing an unrelated cord blood transplantation

A. P. Iori, R. Cerretti, L. De Felice, M. Screnci, A. Mengarelli, A. Romano, M. Caniglia, L. Cerilli, G. Gentile, M. L. Moleti, F. Giona, F. Agostini, I. Pasqua, M. P. Perrone, M. R. Pinto, L. Grapulin, A. M. Testi, P. Martino, G. De Rossi, F. MandelliWilliam Arcese

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

From July 1995 to December 2001, 42 patients with leukemia aged 1-42 years underwent cord blood transplant (CBT) from unrelated, ≤2 antigen HLA mismatched donors. In all, 26 patients were in ≤ 2nd complete remission and 16 in more advanced phase. Conditioning regimens, graft-versus-host disease (GVHD) prophylaxis and supportive policy were uniform for all patients. The cumulative incidence of engraftment was 90% (95% CI: 0.78-0.91). The cumulative incidence of III-IV grade acute- and chronic-GVHD was 9% (95% CI: 0.04-0.24) and 35% (95% CI: 0.21-0.60), respectively. The 4-year cumulative incidence of transplant-related mortality (TRM) and relapse was 28% (95% CI: 0.17-0.47) and 25% (95% CI: 0.14-0.45), respectively. The 4-year overall survival (OS), leukemia-free survival (LFS) and event-free survival (EFS) were 45% (95% CI: 0.27-0.63), 47% (95% CI: 0.30-0.64) and 46% (95% CI: 0.30-0.62), respectively. In multivariate analysis, the most important factor affecting outcomes was the CFU-GM dose, associated with CMV serology (P=0.003 and 0.04, respectively) in influencing OS and with patient sex (P=0.008 and 0.03, respectively) in influencing LFS. Finally, CFU-GM dose was the only factor that affected EFS significantly (P=0.02). In conclusion, the infused cell dose expressed as in vitro progenitor cell growth is highly predictive of outcomes after an unrelated CBT and should be considered the main parameter in selecting cord blood units for transplant.

Original languageEnglish
Pages (from-to)1097-1105
Number of pages9
JournalBone Marrow Transplantation
Volume33
Issue number11
DOIs
Publication statusPublished - Jun 1 2004

Fingerprint

Fetal Blood
Leukemia
Transplantation
Transplants
Granulocyte-Macrophage Progenitor Cells
Graft vs Host Disease
Disease-Free Survival
Survival
Incidence
Serology
HLA Antigens
Stem Cells
Multivariate Analysis
Tissue Donors
Recurrence
Mortality
Growth

Keywords

  • Cord blood transplant
  • Leukemia
  • Prognostic factors
  • Unrelated HSC transplant

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Pre-transplant prognostic factors for patients with high-risk leukemia undergoing an unrelated cord blood transplantation. / Iori, A. P.; Cerretti, R.; De Felice, L.; Screnci, M.; Mengarelli, A.; Romano, A.; Caniglia, M.; Cerilli, L.; Gentile, G.; Moleti, M. L.; Giona, F.; Agostini, F.; Pasqua, I.; Perrone, M. P.; Pinto, M. R.; Grapulin, L.; Testi, A. M.; Martino, P.; De Rossi, G.; Mandelli, F.; Arcese, William.

In: Bone Marrow Transplantation, Vol. 33, No. 11, 01.06.2004, p. 1097-1105.

Research output: Contribution to journalArticle

Iori, AP, Cerretti, R, De Felice, L, Screnci, M, Mengarelli, A, Romano, A, Caniglia, M, Cerilli, L, Gentile, G, Moleti, ML, Giona, F, Agostini, F, Pasqua, I, Perrone, MP, Pinto, MR, Grapulin, L, Testi, AM, Martino, P, De Rossi, G, Mandelli, F & Arcese, W 2004, 'Pre-transplant prognostic factors for patients with high-risk leukemia undergoing an unrelated cord blood transplantation', Bone Marrow Transplantation, vol. 33, no. 11, pp. 1097-1105. https://doi.org/10.1038/sj.bmt.1704500
Iori, A. P. ; Cerretti, R. ; De Felice, L. ; Screnci, M. ; Mengarelli, A. ; Romano, A. ; Caniglia, M. ; Cerilli, L. ; Gentile, G. ; Moleti, M. L. ; Giona, F. ; Agostini, F. ; Pasqua, I. ; Perrone, M. P. ; Pinto, M. R. ; Grapulin, L. ; Testi, A. M. ; Martino, P. ; De Rossi, G. ; Mandelli, F. ; Arcese, William. / Pre-transplant prognostic factors for patients with high-risk leukemia undergoing an unrelated cord blood transplantation. In: Bone Marrow Transplantation. 2004 ; Vol. 33, No. 11. pp. 1097-1105.
@article{a5669ee799874b12afa2d3118f1d65d3,
title = "Pre-transplant prognostic factors for patients with high-risk leukemia undergoing an unrelated cord blood transplantation",
abstract = "From July 1995 to December 2001, 42 patients with leukemia aged 1-42 years underwent cord blood transplant (CBT) from unrelated, ≤2 antigen HLA mismatched donors. In all, 26 patients were in ≤ 2nd complete remission and 16 in more advanced phase. Conditioning regimens, graft-versus-host disease (GVHD) prophylaxis and supportive policy were uniform for all patients. The cumulative incidence of engraftment was 90{\%} (95{\%} CI: 0.78-0.91). The cumulative incidence of III-IV grade acute- and chronic-GVHD was 9{\%} (95{\%} CI: 0.04-0.24) and 35{\%} (95{\%} CI: 0.21-0.60), respectively. The 4-year cumulative incidence of transplant-related mortality (TRM) and relapse was 28{\%} (95{\%} CI: 0.17-0.47) and 25{\%} (95{\%} CI: 0.14-0.45), respectively. The 4-year overall survival (OS), leukemia-free survival (LFS) and event-free survival (EFS) were 45{\%} (95{\%} CI: 0.27-0.63), 47{\%} (95{\%} CI: 0.30-0.64) and 46{\%} (95{\%} CI: 0.30-0.62), respectively. In multivariate analysis, the most important factor affecting outcomes was the CFU-GM dose, associated with CMV serology (P=0.003 and 0.04, respectively) in influencing OS and with patient sex (P=0.008 and 0.03, respectively) in influencing LFS. Finally, CFU-GM dose was the only factor that affected EFS significantly (P=0.02). In conclusion, the infused cell dose expressed as in vitro progenitor cell growth is highly predictive of outcomes after an unrelated CBT and should be considered the main parameter in selecting cord blood units for transplant.",
keywords = "Cord blood transplant, Leukemia, Prognostic factors, Unrelated HSC transplant",
author = "Iori, {A. P.} and R. Cerretti and {De Felice}, L. and M. Screnci and A. Mengarelli and A. Romano and M. Caniglia and L. Cerilli and G. Gentile and Moleti, {M. L.} and F. Giona and F. Agostini and I. Pasqua and Perrone, {M. P.} and Pinto, {M. R.} and L. Grapulin and Testi, {A. M.} and P. Martino and {De Rossi}, G. and F. Mandelli and William Arcese",
year = "2004",
month = "6",
day = "1",
doi = "10.1038/sj.bmt.1704500",
language = "English",
volume = "33",
pages = "1097--1105",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Pre-transplant prognostic factors for patients with high-risk leukemia undergoing an unrelated cord blood transplantation

AU - Iori, A. P.

AU - Cerretti, R.

AU - De Felice, L.

AU - Screnci, M.

AU - Mengarelli, A.

AU - Romano, A.

AU - Caniglia, M.

AU - Cerilli, L.

AU - Gentile, G.

AU - Moleti, M. L.

AU - Giona, F.

AU - Agostini, F.

AU - Pasqua, I.

AU - Perrone, M. P.

AU - Pinto, M. R.

AU - Grapulin, L.

AU - Testi, A. M.

AU - Martino, P.

AU - De Rossi, G.

AU - Mandelli, F.

AU - Arcese, William

PY - 2004/6/1

Y1 - 2004/6/1

N2 - From July 1995 to December 2001, 42 patients with leukemia aged 1-42 years underwent cord blood transplant (CBT) from unrelated, ≤2 antigen HLA mismatched donors. In all, 26 patients were in ≤ 2nd complete remission and 16 in more advanced phase. Conditioning regimens, graft-versus-host disease (GVHD) prophylaxis and supportive policy were uniform for all patients. The cumulative incidence of engraftment was 90% (95% CI: 0.78-0.91). The cumulative incidence of III-IV grade acute- and chronic-GVHD was 9% (95% CI: 0.04-0.24) and 35% (95% CI: 0.21-0.60), respectively. The 4-year cumulative incidence of transplant-related mortality (TRM) and relapse was 28% (95% CI: 0.17-0.47) and 25% (95% CI: 0.14-0.45), respectively. The 4-year overall survival (OS), leukemia-free survival (LFS) and event-free survival (EFS) were 45% (95% CI: 0.27-0.63), 47% (95% CI: 0.30-0.64) and 46% (95% CI: 0.30-0.62), respectively. In multivariate analysis, the most important factor affecting outcomes was the CFU-GM dose, associated with CMV serology (P=0.003 and 0.04, respectively) in influencing OS and with patient sex (P=0.008 and 0.03, respectively) in influencing LFS. Finally, CFU-GM dose was the only factor that affected EFS significantly (P=0.02). In conclusion, the infused cell dose expressed as in vitro progenitor cell growth is highly predictive of outcomes after an unrelated CBT and should be considered the main parameter in selecting cord blood units for transplant.

AB - From July 1995 to December 2001, 42 patients with leukemia aged 1-42 years underwent cord blood transplant (CBT) from unrelated, ≤2 antigen HLA mismatched donors. In all, 26 patients were in ≤ 2nd complete remission and 16 in more advanced phase. Conditioning regimens, graft-versus-host disease (GVHD) prophylaxis and supportive policy were uniform for all patients. The cumulative incidence of engraftment was 90% (95% CI: 0.78-0.91). The cumulative incidence of III-IV grade acute- and chronic-GVHD was 9% (95% CI: 0.04-0.24) and 35% (95% CI: 0.21-0.60), respectively. The 4-year cumulative incidence of transplant-related mortality (TRM) and relapse was 28% (95% CI: 0.17-0.47) and 25% (95% CI: 0.14-0.45), respectively. The 4-year overall survival (OS), leukemia-free survival (LFS) and event-free survival (EFS) were 45% (95% CI: 0.27-0.63), 47% (95% CI: 0.30-0.64) and 46% (95% CI: 0.30-0.62), respectively. In multivariate analysis, the most important factor affecting outcomes was the CFU-GM dose, associated with CMV serology (P=0.003 and 0.04, respectively) in influencing OS and with patient sex (P=0.008 and 0.03, respectively) in influencing LFS. Finally, CFU-GM dose was the only factor that affected EFS significantly (P=0.02). In conclusion, the infused cell dose expressed as in vitro progenitor cell growth is highly predictive of outcomes after an unrelated CBT and should be considered the main parameter in selecting cord blood units for transplant.

KW - Cord blood transplant

KW - Leukemia

KW - Prognostic factors

KW - Unrelated HSC transplant

UR - http://www.scopus.com/inward/record.url?scp=2942722308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942722308&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1704500

DO - 10.1038/sj.bmt.1704500

M3 - Article

C2 - 15094744

AN - SCOPUS:2942722308

VL - 33

SP - 1097

EP - 1105

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 11

ER -